Type 1 Diabetes | The Gillett Health Podcast
About this video
This podcast episode examines emerging research on using GLP-1 medicines in type 1 diabetes, a use Gillett notes current guidelines do not endorse. He discusses a small early-diagnosis study in which, he reports, participants’ blood-sugar control improved markedly and some remained off insulin for a period, and he speculates about preserving remaining beta-cell function. The conversation also covers risks he says clinicians must watch, including ketoacidosis that can occur without very high glucose readings, critiques of guideline screening timelines he considers too passive, and longer-term study findings he interprets as a possible lasting effect on insulin production and appetite.
Key takeaways
- Treat GLP-1 use in type 1 diabetes as investigational, since Gillett notes guidelines still center on insulin
- Small, early, highly selected studies cannot be generalized to everyone with type 1 diabetes
- Learn that ketoacidosis can be missed if glucose alone is checked, as Gillett warns in this discussion
- Question screening recommendations by asking what earlier detection would actually change
- Value long follow-up, because some effects discussed only became apparent years into a study
Episode details: published October 30, 2023 · 313 views · 45:24 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.
← Previous: The TRT Iceberg | [After Hours EP.7] · Next: GLP1s Increase Rick Of Cancer? →
All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)
